Evidence map›Paper›PMID 36094687›Full record

ArticleJournal of thrombosis and thrombolysis2022

The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR

Samantha Pasca, Cojutti PierGiorgio, Federico Pea, Ezio Zanon; the Italian rFXIII Study Group

Erratum issuedOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Rare inherited coagulation disorders: no longer orphan and neglected.Research and practice in thrombosis and haemostasis · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samantha PascaDepartment of Biomedical Sciences (DSB), Padua University Hospital, Padua, Italy. sampasca27@gmail.com.ORCID http://orcid.org/0000-0002-0954-013X
Cojutti PierGiorgioSSD Clinical Pharmacology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Federico PeaSSD Clinical Pharmacology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
Ezio Zanon; the Italian rFXIII Study Group
Azienda USL di Bologna · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFXIII deficiency is a very rare coagulation disorder that can affect equally males and females with an estimated incidence of 1 in 2 million persons worldwide. Due to this rarity, there are only few clinical and pharmacokinetic (PK) data deriving from the real-world.

aimThe aim of this report is to compare head-to-head the pharmacokinetic data of catridecacog derived from the MENTOR

methodsThe PK-profiles of all patients with FXIII deficiency treated with catridecacog at eleven Italian Hemophilia Centers were compared with PK data obtained by Kerlin et al. in the MENTOR

resultsOverall 18 real-world PK were compared with 23 PK derived from the pivotal study. In the RW 55.6% of patients were females, 26.2% in the MENTOR

Indexed as

Factor XIII DeficiencyHemophilia AClinical Trials as TopicFactor XIIIFemaleHumansMaleMentorsRecombinant ProteinsFactor XIIIRecombinant ProteinsFXIII deficiencyFXIII treatmentMENTOR programPharmacokinetics of rFXIIIRecombinant FXIII (rFXIII)

Identifiers

PMID36094687
OpenAlexW4295234061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.